United States Health

US regulators have cut the list of vaccines routinely recommended for all children, citing international comparisons and public trust concerns.

Moderna (NASDAQ:MRNA) officially moved to challenge the multi-billion-dollar seasonal influenza market today, submitting marketing authorization applications for its investigational vaccine, mRNA-1010, to regulators in the U.S., Europe, Canada, and Australia.

Zenas BioPharma (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused on developing transformative immunology-based therapies for autoimmune diseases, today announced positive topline results from the Phase 3 INDIGO registrational trial evaluating obexelimab in patients with Immunoglobulin G4-Related Disease (IgG4-RD).

Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders and neurodegenerative diseases, today reported positive topline results from a Phase 1b signal-seeking study evaluating NMRA-511 as a potential treatment for agitation in patients with Alzheimer's disease.

RedHill Biopharma (NASDAQ:RDHL) is positioning its proprietary oral drug, RHB-102 (Bekinda), as a critical solution to the "discontinuation crisis" facing the blockbuster weight-loss drug market.

Gyre Therapeutics (NASDAQ:GYRE) is moving toward a landmark commercial entry in China after securing alignment with the Center for Drug Evaluation (CDE) on a conditional approval pathway for its lead anti-fibrotic candidate, Hydronidone (F351).

GH Research (NASDAQ:GHRS) shares surged in early trading Monday after the U.S. Food and Drug Administration lifted a long-standing clinical hold on its Investigational New Drug (IND) application for GH001.

Argenx SE (NASDAQ:ARGX) announced a significant leadership transition on Monday, appointing Chief Operating Officer Karen Massey as its new Chief Executive Officer and Executive Director, effective immediately.

HUTCHMED (NASDAQ:HCM) announced today that it has initiated the Phase III stage of its ongoing Phase II/III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine (S+C+AG) as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in China.

Mesoblast (NASDAQ:MESO) has implemented a sweeping reorganization of its Board of Directors, effective January 1, 2026, signaling a definitive shift from a research-heavy biotech to a revenue-driven commercial entity.

The leadership transition follows the company's most transformational period, highlighted by the December 2024 FDA approval and subsequent 2025 launch of Ryoncil (remestemcel-L).

Evotec SE (NASDAQ: EVO) announced on January 2, 2026, the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations.

In this newly created strategic role, Dr. Fakih will lead an integrated function designed to synchronize Evotec’s corporate messaging with its capital markets strategy.

FibroBiologics (NASDAQ:FBLG) took a decisive step toward clinical-stage operations on Wednesday, filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to begin Phase 1/2 trials for its lead psoriasis candidate, CYPS317.